Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934



Filed by the Registrant  ☒                              Filed by a Party other than the Registrant  ☐

Check the appropriate box:


  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Under § 240.14a-12

Urovant Sciences Ltd.

(Name of Registrant as Specified In Its Charter)


(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

Title of each class of securities to which transaction applies:




Aggregate number of securities to which transaction applies:




Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):




Proposed maximum aggregate value of transaction:




Total fee paid:



  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:




Form, Schedule or Registration Statement No.:




Filing Party:




Date Filed:







UROVANT SCIENCES Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be held on September 12, 2019, for Urovant Sciences Ltd. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, go to To submit your proxy while visiting this site, you will need the 12 digit control number in the box below. Under new United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. We have chosen to use these procedures for our 2019 Annual Meeting and need YOUR participation. If the you proxy want materials, to receive you a must paper request or e-mail one. copy There of to is no receive charge a paper to you package for requesting in time a for copy. this In year’s order annual before August meeting, 29, please 2019. make this request on or For a Convenient Way to VIEW Proxy Materials _ and _ VOTE Online go to: Proxy Materials Available to View or Receive: 1. Proxy Statement    2. Annual Report Printed materials may be requested by one of the following methods: INTERNET TELEPHONE *E-MAIL (866) 648-8133 You must use the 12 digit control number located in the shaded gray box below. ACCOUNT NO. * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material. SHARES Company Notice of Annual Meeting Date: Thursday, September 12, 2019 Time: 10:00 A.M. (Local Time) Place: Royal Garden Hotel, 2-24 Kensington High Street, London W8 4PT, United Kingdom The purpose of the Annual Meeting is to take action on the following proposals: The Board of Directors recommends that you vote “FOR” all nominees for director. 1. Election of Directors Nominees 01 Myrtle S. Potter 03 Sef P. Kurstjens, M.D., Ph.D. 05 James Robinson 02 Keith A. Katkin 04 Pierre Legault 06 Frank M. Torti, M.D. The Board of Directors recommends that you vote “FOR” the following.
2. To ratify the selection of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending March 31, 2020, the appointment of Ernst & Young LLP as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the Company’s fiscal year ending March 31, 2020 and the authorization of the Board, through the Audit Committee, to set the remuneration for Ernst & Young LLP as the Company’s auditor for the Company’s fiscal year ending March 31, 2020.
3. To approve the Company’s 2019 Employee Stock Purchase Plan.
4. To approve an amendment to the Company’s 2017 Equity Incentive Plan to increase the number of common shares issuable thereunder from 4,283,431 to 7,283,431.
5. To consider and act upon any other matters which may properly come before the meeting or any adjournment thereof.